Brolucizumab-dbll
(Redirected from Beovu)
What is Brolucizumab–dbll?[edit | edit source]
Brolucizumab–dbll (BEOVU) is a human vascular endothelial growth factor (VEGF) inhibitor.
What are the uses of this medicine?[edit | edit source]
- This medicine is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).
How does this medicine work?[edit | edit source]
- Brolucizumab is a human VEGF inhibitor.
- Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF110, VEGF121, and VEGF165), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2.
- By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Who Should Not Use this medicine ?[edit | edit source]
This medicine cannot be used in patients with:
- Ocular or Periocular Infections
- Active Intraocular Inflammation
- known hypersensitivity to brolucizumab or any of the excipients in BEOVU
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2019.
How should this medicine be used?[edit | edit source]
Recommended Dosage
- The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection monthly (approximately every 25-31 days) for the first three doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8-12 weeks.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- Intravitreal injection: 6 mg/0.05 mL solution in a single-dose vial.
This medicine is available in fallowing brand namesː
- BEOVU
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include:
- vision blurred
- cataract
- conjunctival hemorrhage
- eye pain
- vitreous floaters
= What special precautions should I follow?[edit | edit source]
- Intravitreal injections, including those with BEOVU, have been associated with endophthalmitis and retinal detachment. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay.
- Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported following BEOVU injections. Patients should be instructed to report any change in vision without delay.
- Acute increases in intraocular pressure (IOP) have been seen within 30 minutes of intravitreal injection, including with BEOVU.
- There is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors.
What to do in case of emergency/overdose?[edit | edit source]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- There are no adequate and well-controlled studies of BEOVU administration in pregnant women.
- BEOVU should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Can this medicine be used in children?[edit | edit source]
- The safety and efficacy of BEOVU in pediatric patients has not been established.
What are the active and inactive ingredients in this medicine?[edit | edit source]
Active ingredient:
- BROLUCIZUMAB
Inactive ingredients:
- SUCROSE
- SODIUM CITRATE, UNSPECIFIED FORM
- POLYSORBATE 80
- SODIUM HYDROXIDE
- NITROGEN
- WATER
Who manufactures and distributes this medicine?[edit | edit source]
- Packager: Novartis Pharmaceuticals Corporation
What should I know about storage and disposal of this medication?[edit | edit source]
- Refrigerate BEOVU between 2°C to 8°C (36°F to 46°F). Do not freeze. Store the vial in the outer carton to protect from light.
- Prior to use, the unopened glass vial of BEOVU may be kept at room temperature, 20°C to 25°C (68°F to 77°F) for up to 24 hours.
Brolucizumab-dbll Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju